
H J Zar,1,2 PhD; D P Moore,3 PhD; S Andronikou,4,4 PhD; A C Argent,1 MD (Paediatrics); T Avenant,5 FCPaed (SA); C Cohen,6 PhD; R J Green,7 PhD; G Hizkowitz,8 MSc; P Jeena,7 FCPaed (SA); M P Nicol,9 PhD; A Pillay,10 Cert ID Paed (SA); G Reubenson,9 FCPaed (SA); R Masekela,7 PhD; S A Madhi,10,11 PhD

1 Department of Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital and Faculty of Health Sciences, University of Cape Town, South Africa
2 South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town, South Africa
3 Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa
4 Department of Pediatric Radiology, Perelman School of Medicine, University of Pennsylvania, and Children’s Hospital of Philadelphia, PA, USA
5 Department of Paediatrics and Child Health, Faculty of Health Sciences, University of Pretoria, South Africa
6 Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa
7 Department of Paediatrics and Child Health, Nelson R Mandela School of Medicine, School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
8 Division of Medical Microbiology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, South Africa; and Division of Infection and Immunity, School of Biomedical Sciences, University of Western Australia, Perth, Australia
9 Department of Paediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
10 South African Medical Research Council Vaccine and Infectious Diseases Analytics Unit, University of the Witwatersrand, Johannesburg, South Africa
11 Department of Science and Technology/National Research Foundation: South African Research Chair in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Corresponding author: H J Zar (heather.zar@uct.ac.za)

Background. More comprehensive immunisation regimens, strengthening of HIV prevention and management programmes and improved socioeconomic conditions have impacted on the epidemiology of paediatric community-acquired pneumonia (CAP) in South Africa (SA).

Objectives. To summarise effective preventive strategies to reduce the burden of childhood CAP.

Methods. An expert subgroup reviewed existing SA guidelines and new publications focusing on prevention. Published evidence on pneumonia prevention informed the revisions; in the absence of evidence, expert opinion was used. Evidence was graded using the British Thoracic Society (BTS) grading system.

Recommendations. General measures for prevention include minimising exposure to tobacco smoke or air pollution, breastfeeding, optimising nutrition, optimising maternal health from pregnancy onwards, adequate antenatal care and improvement in socioeconomic and living conditions. Prevention of viral transmission, including SARS-CoV-2, can be achieved by hand hygiene, environmental decontamination, use of masks and isolation of infected people. Specific preventive measures include vaccines as contained in the Expanded Programme on Immunisation schedule, isoniazid prophylaxis for tuberculosis, co-trimoxazole prophylaxis for HIV-infected infants and children who are immunosuppressed, and timely diagnosis of HIV, as well as antiretroviral therapy (ART) initiation. HIV-infected children treated with ART from early infancy, and HIV-exposed children, have similar immunogenicity and immune responses to most childhood vaccines as HIV-unexposed infants.

Validation. These recommendations are based on published evidence supplemented by the consensus opinion of SA paediatric experts, and are consistent with those in published international guidelines.


Advances in the prevention of paediatric pneumonia have led to a reduction in the burden of disease and have lowered the case fatality risk and mortality over the past two decades. Socioeconomic improvements, reduction in perinatal HIV transmission, effective antiretroviral therapy (ART) programmes, introduction of bacterial-conjugate vaccines and improved immunisation coverage have changed the epidemiology and aetiology of childhood pneumonia in South Africa (SA). This section of the revised SA paediatric pneumonia guidelines presents current evidence aimed at prevention of childhood community-acquired pneumonia (CAP).

Prevention of childhood pneumonia

General preventive strategies

General preventive strategies that reduce the incidence and severity of pneumonia are the following, and are summarised in Table 1.

Nutrition

Adequate nutrition and growth monitoring should be encouraged, as malnutrition predisposes children to pneumonia and severe illness. Breastfeeding has been shown to decrease the incidence of pneumonia in young children by up to 32%. Shorter duration of
breastfeeding is associated with pneumonia mortality, particularly among infants <5 months of age.\textsuperscript{[2]} Mortality among infants who are not breastfed compared with exclusively breastfed infants through 5 months of age is ~15-fold higher (relative risk (RR) 14.97; 95% confidence interval (CI) 0.67 - 332.74).\textsuperscript{[2]} Breastfeeding should be encouraged for the first 6 months of a child’s life, irrespective of maternal HIV or ART use,\textsuperscript{[2]} and may be considered for the first 2 years in children living with HIV (CLWH).\textsuperscript{[4]}

### Table 1. Summary: Measures to prevent pneumonia in children

<table>
<thead>
<tr>
<th>General preventive strategies</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nutrition</strong></td>
<td>Malnourished children are at increased risk for severe pneumonia and mortality. Breastfeeding is protective.</td>
</tr>
<tr>
<td><strong>Micronutrient supplementation</strong></td>
<td>Vitamin A should be dosed according to the Road to Health card schedule: 100 000 IU at 6 months; 200 000 IU at 12 months; 200 000 IU at 18 months. From 24 months onwards, 200 000 IU every 6 months from 2 to 5 years of age.</td>
</tr>
<tr>
<td><strong>Vitamin A</strong></td>
<td>Vitamin A deficiency is associated with increased risk for CAP, supplement with vitamin A 400 IU daily.</td>
</tr>
<tr>
<td><strong>Vitamin D</strong></td>
<td>Zinc 10 mg (for infants) and 20 mg (for older children) daily significantly reduces the risk of pneumonia.</td>
</tr>
<tr>
<td><strong>Zinc</strong></td>
<td>Environmental exposure to cigarette smoke or indoor air pollution is strongly correlated with impaired lung health in children.</td>
</tr>
<tr>
<td><strong>Reduction in passive smoking and indoor fuel exposure</strong></td>
<td>Careful attention to limiting transmission of respiratory pathogens reduces the burden of respiratory illness.</td>
</tr>
<tr>
<td><strong>Infection prevention and control and physical distancing</strong></td>
<td>Hand hygiene, Cough etiquette, Decontamination of environmental surfaces, Use of masks.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Specific preventive strategies</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunisation</strong></td>
<td>Administered at:</td>
</tr>
<tr>
<td>BCG</td>
<td>Birth</td>
</tr>
<tr>
<td>Pneumococcal conjugate vaccine</td>
<td>6 weeks, 14 weeks and 9 months</td>
</tr>
<tr>
<td>Hib conjugate vaccine and pertussis vaccine</td>
<td>6 weeks, 10 weeks, 14 weeks and 18 months as part of the hexavalent vaccine</td>
</tr>
<tr>
<td>Influenza vaccine</td>
<td>Not routinely administered in the SA EPI, but should be considered annually for children ≥6 months of age at risk for severe influenza, including those with congenital cardiac disease, chronic lung disease, immunosuppression and neuromuscular disease.</td>
</tr>
<tr>
<td>Measles-containing vaccine</td>
<td>6 months and 12 months</td>
</tr>
<tr>
<td>Combination ART</td>
<td>Expeditious initiation of ART at the earliest opportunity must be implemented routinely for all CLWH to restore immunological function and prevent infectious complications of HIV; ideally, the diagnosis should be made at birth and ART initiated within the first week of life.</td>
</tr>
<tr>
<td><strong>Prophylaxis</strong></td>
<td>Co-trimoxazole prophylaxis is crucial in the prevention of PCP and all-cause mortality in CLWH and those with immunosuppression from other causes; refer to the SA paediatric ART guidelines for details and Box 1.</td>
</tr>
<tr>
<td>Prevention of PCP</td>
<td>INH is an under-utilised preventative strategy in SA children exposed to a household contact with tuberculosis – INH 10 mg/kg × 6 months is recommended.</td>
</tr>
<tr>
<td>Prevention of tuberculosis</td>
<td>CLINH or other underlying immunosuppression with a positive tuberculin skin test, even in the absence of a contact, should be given INH × 6 months. This may also be considered for children newly diagnosed with HIV. The maximum daily dose of INH is 300 mg.</td>
</tr>
<tr>
<td>Prevention of CMV</td>
<td>Although CMV pneumonia is considered to be an important infection in HIV-infected infants, no recommendation on chemoprophylaxis has been adopted.</td>
</tr>
<tr>
<td>Prevention of RSV</td>
<td>The cost of monoclonal antibody prophylaxis (palivizumab) against RSV is very high – therefore, widespread use is not feasible at a programmatic level; ex-premature infants &lt;6 months of age, and those with congenital cardiac disease or chronic lung disease &lt;1 year of age during the course of the RSV season, benefit most from this preventive measure given monthly through the season.</td>
</tr>
</tbody>
</table>

**Notes:**
- **CAP** = community-acquired pneumonia; **BCG** = bacillus Calmette-Guérin; **Hib** = *Haemophilus influenzae* type b; **SA** = South Africa; **EPI** = Expanded Programme on Immunisation; **ART** = antiretroviral therapy; **CLWH** = children living with HIV; **PCP** = *Pneumocystis jirovecii* pneumonia; **IPT** = isoniazid-preventive therapy; **INH** = isoniazid; **CMV** = cytomegalovirus; **RSV** = respiratory syncytial virus.
Micronutrient supplementation

Specific micronutrients that may play a role in the prevention of pneumonia are discussed below:

**Vitamin A.** Vitamin A supplementation reduces severity of respiratory complications of measles. However, a meta-analysis of the impact of vitamin A supplementation on all-cause pneumonia morbidity and mortality showed no consistent effect on pneumonia-specific mortality. Provision of vitamin A supplementation in children with vitamin A deficiency has been associated with improved outcomes.

**Vitamin D.** While empiric therapy using vitamin D in hospitalised children with CAP is not beneficial, observational studies have identified an increased risk of pneumonia in children <5 years old with subclinical vitamin D deficiency (evidence level III). A meta-analysis of the role of vitamin D supplementation in pneumonia prevention found a significant protective effect (evidence level la). However, in a clinical trial conducted in Asian children <5 years of age, oral doses of vitamin D had no protective effect on the incidence of the first episode of pneumonia (evidence level Ib).

**Vitamin E.** There is very little evidence to support vitamin E supplementation for the prevention of pneumonia in children (evidence level IVa). Zinc. Daily prophylactic elemental zinc, 10 mg (infants) and 20 mg (older children), may substantially reduce the incidence of pneumonia, particularly in malnourished children. A pooled analysis of randomised controlled trials of zinc supplementation in well-nourished and malnourished children found that children who received zinc supplementation had a significant reduction in pneumonia incidence compared with those who received placebo (odds ratio (OR) 0.59; CI 0.41 - 0.83) (evidence level la).

**Reduction in tobacco smoke or indoor fuel exposure**

Active and passive exposure to tobacco should be strongly discouraged in women of child-bearing age, particularly among pregnant women, and more generally in the household.

Exposure to fumes from indoor cooking fuels should be limited by opening windows and doors when cooking; the chimney should function well; the stove should be cleaned and maintained; and there should be safe child location practices while fires are burning in the house. The practice of carrying children on caregivers’ backs while cooking is an independent risk factor for pneumonia morbidity and mortality. Children should sleep in rooms separate from where food is cooked (evidence level Ib).

**Infection prevention, control, use of masks and physical distancing**

Hand hygiene and respiratory etiquette are crucial in limiting interpersonal transmission of respiratory pathogens. Reinforcement of hand hygiene decreases the prevalence of respiratory tract illness in adults by 14% (95% CI 11 - 17) in non-pandemic influenza seasons. A systematic review and meta-analysis of the effect of hand hygiene in limiting illness in children suggested that in primary and secondary schools, hand hygiene may decrease the incidence of respiratory tract infections among learners (evidence level la). Although young children are not generally able to adhere to respiratory etiquette practices, older children, caregivers and health workers should adopt these practices to limit the transmission of respiratory pathogens.

Universal use of cloth face masks by children and adults in public is an effective public health intervention to reduce transmission of respiratory viruses, including SARS-CoV-2, in addition to other public health measures. In health facilities, all healthcare workers should wear a surgical mask in addition to practising hand hygiene, physical distancing and environmental decontamination to prevent SARS-CoV-2 transmission.

**Specific preventive strategies**

**Immunisation**

**Routine immunisations**

All children should receive routine vaccines, including bacillus Calmette-Guérin (BCG), measles, diphtheria-pertussis-tetanus (DPT) toxoid, _Haemophilus influenzae_ type b (Hib), polysaccharide-protein conjugate vaccine (HibCV) and pneumococcal polysaccharide-protein conjugate vaccine (PCV) as per the SA immunisation schedule. The nature and degree of immunosuppression in CLWH may impact on the efficacy and duration of vaccine-induced protection. CLWH treated with ART from early infancy, and responding well to such therapy, demonstrate similar immunogenicity and anamnestic immune responses to most childhood vaccines compared with HIV-unexposed infants. HIV-exposed uninfected (HEU) infants may have lower concentrations of transplacental acquired antibodies for some vaccine-preventable diseases, which could increase their susceptibility to pneumonia during early infancy. The immune responses to all vaccines are, however, similar or more immunogenic for HEU than for HIV-unexposed infants, and there is similar persistence of protective antibody concentrations and memory responses.

**Specific vaccines**

**BCG vaccine.** _Mycobacterium tuberculosis_ may be a direct pathogen in pneumonia or may predispose to bacterial infection (including from pneumococci). A birth dose of BCG vaccine is effective in preventing disseminated tuberculosis in young children, but has variable effectiveness (average 50%; range 0 - 84% effectiveness) in prevention of pulmonary tuberculosis, with lower effectiveness in studies on children from tropical countries. A birth dose has also been shown to have nonspecific benefits in improving overall child survival in some settings.

**Pneumococcal vaccine.** Multiple post-licensure effectiveness studies (using 10- and 13-valent PCV) in a diversity of settings have demonstrated a 17% (95% CI 11 - 22) and 31% (95% CI 26 - 35) reduction in hospitalisation rates for clinically and radiologically confirmed pneumonia, respectively. In children aged 24 - 59 months a meta-analysis found a reduction of 9% (95% CI 5 - 14) and 24% (95% CI 12 - 33) in hospitalisation rates for clinically and radiologically confirmed pneumonia, respectively (evidence level Ia).

In SA, PCV (currently 13-valent) is administered at 6 and 14 weeks of age, followed by a booster dose at 9 months of age (evidence level Ib). This schedule has been shown to be effective in reducing all-cause pneumonia hospitalisation by 33% and 39% in CLWH and HIV-uninfected children, respectively.

The 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23) is recommended for children >2 years old, who are at risk of developing invasive pneumococcal disease, including those with sickle cell disease, chronic pulmonary disease and cardiovascular disease, and is included in the SA Essential Drugs List for paediatrics for administration to such patients. It should be preceded by a single dose of PCV, given at least 1 month before (evidence level III).

The need for further booster doses of PCV in older CLWH remains to be determined, but the indirect effect of childhood PCV immunisation in reducing transmission and circulation of vaccine-serotype pneumococci could mitigate waning of immunity in CLWH and other high-risk groups that remain susceptible to developing severe pneumonia in later childhood.
Health Organization (WHO) currently recommends that a booster dose of PCV may be considered in the second year of life in CLWH (evidence level II).[47]

**Hib conjugate vaccine.** Vaccination with HibCV, as part of a combination vaccine, is recommended as a 3-dose primary series, and includes a booster dose at 15 - 18 months of age in SA. HibCV is less effective in CLWH not on ART;[48] however, the immunogenicity of the vaccine and persistence of memory responses in the second year of life are similar in CLWH vaccinated when initially initiated on ART at the time of immunisation.[49]

**Pertussis vaccine.** Pertussis remains one of the most poorly controlled vaccine-preventable diseases globally and causes severe disease in young infants (especially in those <3 months of age) and incompletely immunised children (evidence level Ib).[50,51]

Pertussis vaccine formulations include whole-cell containing (wp) and Bordetella pertussis protein-only component acellular vaccines (aP). Whole-cell pertussis vaccines, but not aP protein-containing vaccines, induce mucosal immunity and protect against B. pertussis mucosal infection and transmission.[52] Furthermore, the duration of protection of wp is 8 - 12 years compared with 4 - 5 years for aP vaccines.[53] Currently, only aP-containing combination vaccines are available in SA.

Pertussis outbreaks have been temporally associated with transitioning from wp to aP formulations in many high-resource settings, attributed to the waning of immunity in the absence of repeat booster doses at school entry and beyond.[54] Children primed with aP-containing vaccines should receive booster doses of aP vaccines (dTAp) at school entry and possibly every 10 years thereafter (not yet part of the Expanded Programme on Immunisation (EPI)) (evidence level II).[55] Prevention of pertussis in young infants, who are at greatest risk of severe disease, is not achievable through infant immunisation, and transitioning from wp to aP could increase the burden of pertussis in this group.[54] Acellular pertussis vaccination of pregnant women is 90% effective in reducing pertussis in infants <3 months of age (evidence level Ia).[55]

**Influenza vaccine.** Only the sub-unit inactivated influenza vaccine is available in SA for annual administration. There are limited data on its efficacy in children, ranging from 33% to 73%, depending on vaccine preparation and influenza subtype targeted.[56] Current evidence suggests that influenza vaccination is safe in CLWH; however, a randomised controlled trial failed to demonstrate vaccine efficacy.[57] Nonetheless, there remains a recommendation that CLWH should be offered influenza vaccination before the start of winter, particularly if they have underlying chronic lung disease (evidence level III).

Children >6 months of age with underlying medical conditions are considered a high risk for complications of influenza, and are prioritised for annual vaccination. Such children comprise those with chronic pulmonary disease (including asthma), cardiac disease, chronic renal or hepatic diseases, diabetes mellitus, metabolic disorders, sickle cell anaemia and other haemoglobinopathies, morbid obesity, immunosuppression, cerebral palsy or other neuromuscular conditions.[58] Family members and siblings of such patients should also be vaccinated.[59] Two doses of inactivated influenza vaccine, administered 1 month apart, are recommended for children 6 months - 9 years of age who have never been vaccinated; and a single dose if immunised in previous seasons.[59]

Recent randomised controlled trials have demonstrated that influenza vaccination of pregnant women was 50% efficacious in reducing polymerase chain reaction (PCR)-confirmed influenza illness in their infants until 24 weeks of age. In SA and Mali, vaccination of pregnant women was more effective in preventing influenza illness in infants during the first 3 months of life (vaccine efficacy ~ 85%), with subsequent waning and a non-significant reduction between 3 and 6 months of age.[60] Maternal influenza vaccination also reduced all-cause clinically diagnosed severe pneumonia or pneumonia hospitalisation by 30% in infants during the first 6 months.[61,62] Influenza immunisation should ideally be administered prior to the onset of the influenza season (which typically occurs from May to September in SA).[61,62] but can also be given during the influenza season. Due to the potential of year-on-year genetic drift of seasonal influenza virus strains, current vaccine formulations are updated annually, and a repeat vaccination is required each year.

**Measles vaccine.** Measles remains a public health concern, and failure to achieve and sustain high immunisation coverage rates (>95%) against this highly contagious virus results in ongoing outbreaks in a diversity of settings, including SA.[63,64] Recent changes in the epidemiology of measles include a greater susceptibility of disease in very young infants (as early as 4 months of age).[65] This is due to lower antibody concentrations in pregnant women who have acquired immunity through vaccination, rather than through wild-type virus exposure, as well as possible waning of immunity in women living with HIV.[66,67]

The WHO recommends that children receive 2 doses of the measles vaccine, the first at 9 months of age and a booster dose at 15 - 18 months of age.[68] However, for infants born to women living with HIV, and in settings with a high risk of measles in young infants, an additional dose is recommended at 6 months of age.[69] In SA, a 2-dose measles vaccination schedule is recommended, administered at 6 and 12 months of age. This induces seroprotective titres in ~55% of infants following the first dose of vaccine, and in >98% in HIV-exposed and HIV-unexposed children after the second dose of vaccine.[70]

**Combination antiretroviral therapy**

The use of ART to reconstitute immunity is very effective for decreasing the incidence of pneumonia and opportunistic infections in CLWH. Combination ART should be initiated on diagnosis of HIV in all children, irrespective of clinical or immunological staging. Screening for HIV infection in newborns of HIV-infected women by means of PCR testing at birth and repeated PCR testing during the infant and breastfeeding period is standard of care in SA, with initiation of ART as soon as possible after confirmation of HIV infection, and continued lifelong thereafter.

**Prophylaxis**

**Prevention of Pneumocystis jirovecii pneumonia.** Updated recommendations for the management of CLWH were published in 2019 (South African ART guidelines) (Box 1).[71]

Although the WHO recommends Pneumocystis jirovecii pneumonia (PCP) prophylaxis for HEU infants from 4 to 6 weeks of age until HIV infection has been excluded after complete cessation of breastfeeding, two southern African randomised controlled trials have shown that co-trimoxazole confers no survival advantage over placebo in this subset of children; therefore, this is not recommended in SA.[72,73]

**Prevention of tuberculosis.** All children <5 years of age exposed to a household tuberculosis contact or other close tuberculosis contact should be given isoniazid preventive therapy (IPT) (10 mg/kg; maximum dose 300 mg) daily for 6 months once tuberculosis disease has been excluded. CLWH exposed to a household contact should be given prophylaxis for 6 months, irrespective of their age. A 6-month course of IPT should also be given to tuberculin skin test (TST)-positive CLWH, even in the absence of a known household contact.[72]
There are conflicting data on the use of primary IPT in CLWH in the absence of a tuberculosis contact.\textsuperscript{[72,73]} Newly HIV-diagnosed and clinically symptomatic CLWH may benefit from a 6-month course of IPT, irrespective of TST results.

Short-course preventive therapy using rifampicin and isoniazid must not be used in the context of tuberculosis prevention in HIV-exposed neonates born to mothers with active tuberculosis, as the rifampicin component interferes with the prevention of mother-to-child transmission (PMTCT) regimen.\textsuperscript{[73]}

Current WHO guidelines encourage use of preventive therapy with multidrug-resistant tuberculosis (MDR-TB) based on individualised risk assessment for children exposed to source cases. In children exposed to a source case with ofloxacin-susceptible \textit{M. tuberculosis}, a 6-month course of ofloxacin, ethambutol and high-dose isoniazid has been found to be well tolerated.\textsuperscript{[76]}

\textbf{Prevention of cytomegalovirus disease in HIV-infected children.} There is no evidence to support a specific intervention in the prevention of cytomegalovirus (CMV) disease in CLWH.\textsuperscript{[77]}

\textbf{Prevention of respiratory syncytial virus.} Although the humanised monoclonal-specific antibody for the prevention of respiratory syncytial virus (RSV) infections (palivizumab) is available, it is very expensive. Children most likely to benefit are those at risk of severe RSV infection, i.e. babies born prematurely who are <6 months of chronological age at the onset of the RSV season, or children with chronic lung disease or congenital cardiac disease who are <1 year of age at the onset of the RSV season.\textsuperscript{[78]}

A meta-analysis on the effectiveness of palivizumab against RSV hospitalisation reported 71% (95\% CI 46 - 84) effectiveness in infants born at <35 weeks' gestational age, and ~45\% in those with chronic lung disease and congenital heart disease (evidence level Ia).\textsuperscript{[79]}

Palivizumab should be given monthly for the duration of the RSV season (from February to July) in most of SA.\textsuperscript{[80,81]}

Other strategies for prevention of severe RSV disease in infants, including antenatal vaccination of expectant mothers and long-acting monoclonal antibody preparations, are currently under investigation.

\textbf{Conclusions}

Improvements in the EPI, through inclusion of protein-polysaccharide conjugate vaccines targeting Hib and pneumococcus, and expansion of the ART programme to prevent paediatric HIV infection and treat CLWH, have reduced the burden of CAP in SA children. However, the socioeconomic determinants of health still place the majority of children in SA at risk of becoming ill with pneumonia, and concerted efforts are needed for intersectoral collaboration to bring about sustained reductions in the pneumonia burden of SA children. Pneumonia-specific preventive strategies are highly effective and require ongoing implementation and monitoring.

\textbf{Declaration.} None.

\textbf{Acknowledgements.} None.

\textbf{Author contributions.} The prevention group was chaired by SAM, with members DPM and HJZ. This group reviewed the evidence and wrote the manuscript. RM led a group on HIV considerations, with AP; findings from this group have been incorporated into this manuscript. All authors reviewed and contributed to the final manuscript.

\textbf{Conflicts of interest.} None.
evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria.

Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail

in infants pertussis and the success of maternal immunization. Expert Rev Vaccines


Barger-Kamate B, Knoll MD, Kagucia EW, et al. Pertussis-associated pneumonia in infants and


Omer SB, Dittrich S, Kowalewski C, et al. Maternal influenza immunization and prevention of severe

Omer SB, Dittrich S, Kowalewski C, et al. Maternal influenza vaccination and prevention of severe

Mutsaerts EAML, Nunes MC, Bhikha S, et al. Immunogenicity and safety of an early measles


Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-


Mellors JW, Munster VJ,ropped: 7315-7318. https://doi.org/10.1093/infdis/jix475

National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in


National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in


Mutsaerts EAML, Nunes MC, Bhikha S, et al. Immunogenicity and safety of an early measles


Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-


Mellors JW, Munster VJ,ropped: 7315-7318. https://doi.org/10.1093/infdis/jix475

National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in


National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in


Mutsaerts EAML, Nunes MC, Bhikha S, et al. Immunogenicity and safety of an early measles


Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-


Mellors JW, Munster VJ,ropped: 7315-7318. https://doi.org/10.1093/infdis/jix475

National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in


National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in


Mutsaerts EAML, Nunes MC, Bhikha S, et al. Immunogenicity and safety of an early measles


Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-


Mellors JW, Munster VJ,ropped: 7315-7318. https://doi.org/10.1093/infdis/jix475

National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in


National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in


Mutsaerts EAML, Nunes MC, Bhikha S, et al. Immunogenicity and safety of an early measles


Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-


Mellors JW, Munster VJ,ropped: 7315-7318. https://doi.org/10.1093/infdis/jix475

National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in


National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in


Mutsaerts EAML, Nunes MC, Bhikha S, et al. Immunogenicity and safety of an early measles


Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-


Mellors JW, Munster VJ,ropped: 7315-7318. https://doi.org/10.1093/infdis/jix475

National Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in